<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="775">
  <stage>Registered</stage>
  <submitdate>14/09/2005</submitdate>
  <approvaldate>14/09/2005</approvaldate>
  <nctid>NCT00168376</nctid>
  <trial_identification>
    <studytitle>A Randomised Double-Blind Trial of Targeted Repetitive Transcranial Magnetic Stimulation in Major Depressive Disorder</studytitle>
    <scientifictitle>A Randomised Double-Blind Trial of Targeted Repetitive Transcranial Magnetic Stimulation in Major Depressive Disorder</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>57/04</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Major Depressive Disorder</healthcondition>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Depression</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - Transcranial Magnetic Stimulation

Treatment: devices: Transcranial Magnetic Stimulation


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The outcome measure used is the MADRS (Montgomery-Asberg Depression Rating Scale). This is administered at baseline and on a fortnightly basis.</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Other outcome measures administered fortnightly are: BPRS (Brief Psychiatric Rating Scale), CORE (measure of melancholic symptoms), BDI (Beck Depression Inventory), CGI (Clinical Global Impression Scale), GAF (Global Assessment of Functioning Scale).</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Moderate to severe depressive symptoms as indicated as MADRS &gt;20

          -  Failure to respond to a minimum of two antidepressant medications

          -  No increase or initiation of new antidepressant therapy in the four weeks prior to
             entering the trial</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Have an unstable medical condition, neurological disorder or any history of seizure
             disorder or are currently pregnant or lactating

          -  Previous brain injury or surgery, any metal clips, plates or other metal items in the
             head, cardiac pacemaker

          -  In the opinion of the investigator, are a sufficient suicide risk to require immediate
             electroconvulsive therapy

          -  Have a current DSMIV diagnosis of substance abuse or dependence disorder, a diagnosis
             of a personality disorder or another axis 1 disorder</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Educational/counselling/training</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/07/2004</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/04/2006</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Alfred Psychiatry Research Centre - Melbourne</hospital>
    <postcode>3181 - Melbourne</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>The Alfred</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The study will involve a 3-week (15 session) randomized double-blind clinical trial of two
      repetitive transcranial magnetic stimulation (rTMS) conditions in patients with treatment
      resistant depression. rTMS site selection will be localized from structural MRI scans.

      The patients will be randomized to one of two conditions

        1. rTMS targeted to the border of Brodmann area 46 and Brodmann area 9,

        2. rTMS targeted to premotor cortex (this condition will act as the non-dorsolateral
           prefrontal cortex targeted control).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00168376</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Paul B Fitzgerald, MBBS, PhD</name>
      <address>Alfred Psychiatry Research Centre</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>